These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Naftidrofuryl in arterial obstructive disease: A systematic revue of the literature]. Bourrion B; Hazard A; Baltazard H; Sebbag P; Fournier L; François M Rev Med Interne; 2020 Feb; 41(2):89-97. PubMed ID: 31669163 [TBL] [Abstract][Full Text] [Related]
25. [Evaluation of the efficacy and tolerance of naftidrofuryl in patients presenting with exertional angina. Multicenter double-blind versus placebo study]. Hirsch JL; Bensoussan JJ; Mosnier M; Lehert P Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):137-45. PubMed ID: 12555338 [TBL] [Abstract][Full Text] [Related]
26. [The antagonist of type-II serotonin receptors naftidrofuryl in the treatment of patients with intermittent claudication]. Komarov AL; Panchenko EP; Eshkeeva AR; Dobrovol'skiĭ AB; Titaeva EV; Karpov IuA Ter Arkh; 1996; 68(2):49-53. PubMed ID: 8771659 [TBL] [Abstract][Full Text] [Related]
27. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication. Hong H; Mackey WC Clin Ther; 2014 Aug; 36(8):1290-301. PubMed ID: 25012728 [TBL] [Abstract][Full Text] [Related]
28. Naftidrofuryl in quality of life (NIQOL). A Belgian study. D'Hooge D; Lehert P; Clement DL Int Angiol; 2001 Dec; 20(4):288-94. PubMed ID: 11782694 [TBL] [Abstract][Full Text] [Related]
31. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. Adhoute G; Andreassian B; Boccalon H; Cloarec M; Di Maria G; Lefebvre O; Mondine P; Plagnol P; Pointel JP; Quancard X J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S75-80. PubMed ID: 1369725 [TBL] [Abstract][Full Text] [Related]
32. [Evaluation of the analgesic effect of naftidrofuryl in permanent ischemia in patients with arterial diseases. Double-blind versus placebo study]. Testart J; Guidicelli H; Glanddier G; Mosnier M Ann Cardiol Angeiol (Paris); 1994 Nov; 43(9):542-7. PubMed ID: 7864561 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Meng Y; Squires H; Stevens JW; Simpson E; Harnan S; Thomas S; Michaels J; Stansby G; O'Donnell ME Angiology; 2014 Mar; 65(3):190-7. PubMed ID: 23378195 [TBL] [Abstract][Full Text] [Related]
36. The effect of naftidrofuryl on transcutaneous oxygen tension during a treadmill test in patients with peripheral arterial occlusive disease. Mouren X; Caillard P; Bensoussan JJ; Massonneau M; Gamand S; Stevens WH Vasc Med; 1998; 3(1):9-14. PubMed ID: 9666526 [TBL] [Abstract][Full Text] [Related]
37. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Kieffer E; Bahnini A; Mouren X; Gamand S Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997 [TBL] [Abstract][Full Text] [Related]